TherapeuticsMD, Inc.

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

TXMD$1.74+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(Unaudited - in thousands)

	Six Months Ended June 30,
	2026	2025
Cash flows from operating activities:
Net income (loss)	$250	$(102)
Less: Loss from discontinued operations, net of income taxes	(17)	(11)
Net income (loss) from continuing operations	267	(91)
Adjustments to reconcile net income (loss) to net cash provided by continuing operating activities:
Depreciation and amortization	189	191
Write-off of patents	13	88
Share-based compensation costs	6	24
Amortization of right of use assets	465	370
Changes in operating assets and liabilities:
Prepaid and other current assets	(101)	(192)
Other assets	1,267	872
Accounts payable	83	92
Accrued expenses and other current liabilities	71	84
Lease liabilities	(537)	(445)
Other non-current liabilities	—	87
Total adjustments	1,456	1,171
Net cash provided by continuing operating activities	1,723	1,080
Discontinued operations:
Net cash used in operating activities	(17)	(70)
Net cash used in discontinued operations	(17)	(70)
Net increase in cash and cash equivalents	1,706	1,010
Cash and cash equivalents - continuing operations, beginning of period	7,483	5,059
Total cash and cash equivalents, end of period	$9,189	$6,069

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.